Literature DB >> 17690502

The relationship between FDG uptake in PET scans and biological behavior in breast cancer.

Wataru Shimoda1, Mitsuhiro Hayashi, Koji Murakami, Tetsunari Oyama, Masakatsu Sunagawa.   

Abstract

BACKGROUND: Positron emission tomography (PET) is a non-invasive imaging modality used in the diagnosis and staging of breast cancer. However, several factors can affect fluoro-deoxyglucose (FDG) uptake by a tumor. To clarify the parameters that most affect FDG accumulation in tumors, the relationship between standardized uptake values (SUVs) and clinicopathological factors and immunohistopathological analysis was investigated in breast cancer.
MATERIAL AND METHODS: PET studies were performed preoperatively on 37 patients with breast carcinoma. SUVs were counted at one hour (early phase) and at two hours (delayed phase) after FDG injection. The relationships between SUVs and 13 clinical, pathological and immunohistchemical factors were studied.
RESULTS: A significant association was found between FDG accumulation and early and delayed phase mitotic counts (p=0.0018 and 0.0010, respectively), Ki67 positive cell percentage (p=0.0098 and 0.0062, respectively), and nuclear grade (p=0.0232 and 0.0195, respectively). On the other hand, nodal status weakly correlated with the delayed phase (p=0.0907). However, other clinicopathological parameters and immunohistopathological status, which included tumor size, age, histology, estrogen receptor, progesterone receptor and Her2/neu overexpression, did not correlate significantly with FDG uptake.
CONCLUSION: Mitotic count and Ki67 reflect cellular aggressiveness. These parameters were strongly correlated with tracer uptake. Thus our data suggested that the biological behavior of breast cancer is reflected in the variation of FDG uptake by the tumor. However, whether FDG uptake is a true prognostic and predictive factor remains to be confirmed in larger studies over an extended period of time.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17690502     DOI: 10.2325/jbcs.14.260

Source DB:  PubMed          Journal:  Breast Cancer        ISSN: 1340-6868            Impact factor:   4.239


  34 in total

1.  Assessment of response to endocrine therapy using FDG PET/CT in metastatic breast cancer: a pilot study.

Authors:  Nina Mortazavi-Jehanno; Anne-Laure Giraudet; Laurence Champion; Florence Lerebours; Elise Le Stanc; Veronique Edeline; Olivier Madar; Dominique Bellet; Alain Paul Pecking; Jean-Louis Alberini
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-12-20       Impact factor: 9.236

2.  A virtual clinical trial comparing static versus dynamic PET imaging in measuring response to breast cancer therapy.

Authors:  Kristen A Wangerin; Mark Muzi; Lanell M Peterson; Hannah M Linden; Alena Novakova; David A Mankoff; Paul E Kinahan
Journal:  Phys Med Biol       Date:  2017-02-13       Impact factor: 3.609

3.  Basal ¹⁸F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography as a prognostic biomarker in patients with locally advanced breast cancer.

Authors:  Ana María García Vicente; Ángel Soriano Castrejón; Jesús Fernando López-Fidalgo; Mariano Amo-Salas; María Del Mar Muñoz Sanchez; Ruth Álvarez Cabellos; Ruth Espinosa Aunión
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-07-09       Impact factor: 9.236

4.  A preliminary study to propose a diagnostic algorithm for PET/CT-detected incidental breast lesions: application of BI-RADS lexicon for US in combination with SUVmax.

Authors:  Mehrdad Bakhshayeshkaram; Yalda Salehi; Mehrshad Abbasi; Razieh Hashemi Beni; Sharareh Seifi; Maryam Hassanzad; Hamid Reza Jamaati; Farahnaz Aghahosseini
Journal:  Eur Radiol       Date:  2019-03-18       Impact factor: 5.315

5.  Correlation of high 18F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer.

Authors:  David Groheux; Sylvie Giacchetti; Jean-Luc Moretti; Raphael Porcher; Marc Espié; Jacqueline Lehmann-Che; Anne de Roquancourt; Anne-Sophie Hamy; Caroline Cuvier; Laetitia Vercellino; Elif Hindié
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-11-06       Impact factor: 9.236

6.  Semi-quantitative lymph node assessment of (18)F-FDG PET/CT in locally advanced breast cancer: correlation with biological prognostic factors.

Authors:  Ana María García Vicente; Angel Soriano Castrejón; Miguel Angel Cruz Mora; Ana González Ageitos; María del Mar Muñoz Sánchez; Alberto León Martín; Ruth Espinosa Aunión; Fernanda Relea Calatayud; Vicente Muñoz Madero; Ignacio Chacón López-Muñiz; Jose Manuel Cordero García; Germán Andrés Jiménez Londoño
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-09-28       Impact factor: 9.236

7.  Degree of tumor FDG uptake correlates with proliferation index in triple negative breast cancer.

Authors:  Julia Tchou; Seema S Sonnad; Meredith R Bergey; Sandip Basu; John Tomaszewski; Abass Alavi; Mitchell Schnall
Journal:  Mol Imaging Biol       Date:  2009-12-12       Impact factor: 3.488

Review 8.  18F-FDG uptake in lung, breast, and colon cancers: molecular biology correlates and disease characterization.

Authors:  Hossein Jadvar; Abass Alavi; Sanjiv S Gambhir
Journal:  J Nucl Med       Date:  2009-10-16       Impact factor: 10.057

9.  Accuracy of integrated FDG-PET/contrast-enhanced CT in detecting pelvic and paraaortic lymph node metastasis in patients with uterine cancer.

Authors:  Kazuhiro Kitajima; Koji Murakami; Erena Yamasaki; Yasushi Kaji; Kazuro Sugimura
Journal:  Eur Radiol       Date:  2009-01-29       Impact factor: 5.315

10.  A 2-helix small protein labeled with 68Ga for PET imaging of HER2 expression.

Authors:  Gang Ren; Rong Zhang; Zhe Liu; Jack M Webster; Zheng Miao; Sanjiv S Gambhir; Faisal A Syud; Zhen Cheng
Journal:  J Nucl Med       Date:  2009-08-18       Impact factor: 10.057

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.